Diagnosis* | Antibody |
Smooth muscle tumors | Desmin, h-caldesmon, smooth muscle actin |
Fumarate hydratase deficiency | FH and 2SC |
STUMP | ATRX, RB, PTEN, p53, DAXX, MTAP, MDM2 |
Rhabdomyosarcoma | Desmin, myogenin, MyoD1, myogenin |
Inflammatory myofibroblastic tumor | ALK, ROS1 |
Endometrial stromal tumors | CD10, IFITM1, Cyclin D1, BCOR, ER, PR |
SMARC-deficient tumors | BRG1 (SMARCA4), BRM (SMARCA2), INI/BAF47(SMARCB1), MMR (MLH1, PMS2, MSH6, MSH2) |
PEComa | HMB45, Melan A, Cathepsin K, TFE3 |
Fibrosarcoma | pan-TRK, CD34, S100 |
Solitary fibrous tumor | STAT6, CD34 |
Extraintestinal gastrointestinal stromal tumor | c-KIT, DOG1 |
Complex genomic sarcomas (LMS, UUS) | p53 (usually aberrant) |
Simple genomic sarcomas (LG-ESS, HG-ESS, NTRK, etc) | p53 (usually wild-type) |
Uterine tumor resembling ovarian sex cord tumor | Calretinin, inhibin |
*The diagnosis can be established by a combination of these antibodies and integrated into the appropriate morphological context.
HG-ESS, high-grade endometrial stromal sarcoma; LG-ESS, low-grade endometrial stromal sarcoma; LMS, leiomyosarcoma; NTRK, neurotrophic tyrosine receptor kinase; PEComa, perivascular epithelial cell tumor; STUMP, smooth muscle tumor of uncertain malignant potential; UUS, undifferentiated uterine sarcoma.